Novartis

News

Novartis completes spin-out of Alcon eye unit

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.

News

US drug cost body calls for SMA drug price cuts

A US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular atrophy (SMA) drug, while the $4-$5 million Novartis is suggesting for a

News

Fusion raises $105m for radiopharmaceutical trials

Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas

News

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline.

News

Teva's migraine drug Ajovy approved in Europe

Teva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Novartis and Eli Lilly.

News

MS drug market heats up as FDA backs Novartis' new pill

The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene.

Novartis completes spin-out of Alcon eye unit

US drug cost body calls for SMA drug price cuts

Fusion raises $105m for radiopharmaceutical trials

Novartis buys NASH biotech IFM Tre in potential $1.575 bn de...

Teva's migraine drug Ajovy approved in Europe

MS drug market heats up as FDA backs Novartis' new pill

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks